Neurokinin 3 receptor antagonism for menopausal hot flashes

Alexander N Comninos; Waljit S Dhillo

doi:10.1016/j.cell.2023.07.011

Neurokinin 3 receptor antagonism for menopausal hot flashes

Cell. 2023 Aug 3;186(16):3332-3332.e1. doi: 10.1016/j.cell.2023.07.011.

Authors

Alexander N Comninos¹, Waljit S Dhillo²

Affiliations

¹ Section of Endocrinology & Investigative Medicine, Imperial College London, London, UK; Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
² Section of Endocrinology & Investigative Medicine, Imperial College London, London, UK; Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK. Electronic address: w.dhillo@imperial.ac.uk.

PMID: 37541194
DOI: 10.1016/j.cell.2023.07.011

Abstract

Menopausal hot flashes are common and debilitating. Menopausal Hormone Therapy (MHT) is effective for hot flashes but has risks and side effects that limit its use. NK3 receptor antagonism has emerged as a novel therapeutic strategy, leading to the recent FDA approval of fezolinetant, a first-in-class nonhormonal treatment for menopausal hot flashes. To view this Bench to Bedside, open or download the PDF.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Hot Flashes* / drug therapy
Humans
Menopause*
Receptors, Neurokinin-3* / antagonists & inhibitors
Thiadiazoles* / therapeutic use

Substances

Receptors, Neurokinin-3
fezolinetant
Thiadiazoles

Abstract

Publication types

MeSH terms

Substances

Grants and funding